MedPharm strengthens management on back of US success
Appointments come as global leader in contract topical and transdermal pharmaceutical development benefits from increased revenues.
MedPharm has appointed Simon Redgrove as Chairman of the Board and Dr Jeremy Drummond as Vice President of Business Development and member of the Executive Leadership Team. The appointments come as MedPharm benefits from increased revenues as a result of integrating services with its fully functioning US laboratory facilities in North Carolina.
Simon Redgrove has built a strong reputation in the financial business community for nurturing the growth of businesses. He will provide overall guidance to the board and brings a depth of knowledge of fostering companies like MedPharm through critical growth stages in their development. Simon was a founder and managing director of Cavanagh Group PLC in 1996 which he took to the AIM market in 2001 and sold to Close Brothers in 2011. Subsequently as Head of Advice at Close Brothers Asset Management he was instrumental in turning around the business. In 2015 Simon cofounded MunnyPot Ltd, a low cost online investment service.
Simon Redgrove stated: “I am delighted to be joining the MedPharm board as Chairman. The company has a solid track record of growth over the last nineteen years. I am looking forward to helping MedPharm grow on the back of the many exciting innovations it is bring to its services to support customers’ development projects.”
“We are very pleased to have secured Simon Redgrave as our Chairman,” said Dr Andy Muddle, MedPharm’s CEO and Co-founder. “We will look to use his different perspective and strong business acumen to ensure MedPharm continues to grow in line with its ambitious strategic plan”.
Dr Jeremy Drummond joins MedPharm having spent over 20 years in roles of increasing responsibility leading the commercial supply of product and services to pharmaceutical companies across the globe. His role is to help clients understand how MedPharm can mitigate risk and shorten their development timelines of their generic or proprietary products. He started his career as a formulation scientist at major multinationals and has a PhD in organic chemistry from the University of Cambridge.
Jeremy Drummond commented: “MedPharm has a fantastic reputation in the pharmaceutical development marketplace and is continuing to bring new ideas to help reduce the cost and reduce the time to market for our customers’ topical and transdermal development programmes. I look forward to helping the team expand these benefits to customers focused on ear, airway and eye indications where MedPharm has demonstrated it has much to offer.”
“Jeremy brings a wealth of experience to the Executive Team”, said Prof Marc Brown, MedPharm’s Chief Scientific Officer and Co-Founder. “His commercial experience and knowledge is strongly complimented by his technical background and we are looking forward to him driving forward MedPharm’s presence in the global pharmaceutical CRO marketplace.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance